The above clinical data suggest that the IL-21 neutralization strategy may represent a promising immunotherapeutic approach that may enhance PD-1 blockade-based tumor immunotherapy by targeting Treg-mediated immune evasion in only patients with high expression of IL-21 and PD-L1. The gene discussed is IL21; the disease is neoplasm.